Fig. 6: Effect of FOXA2 haploinsufficiency on iPSC-derived beta cells.
From: Aberrant development of pancreatic beta cells derived from human iPSCs with FOXA2 deficiency
Representative immunofluorescent images (A) and flow cytometry histograms (B) showing the expression of INSULIN (INS), NKX6.1, C-PEPTIDE (C-PEP), and GLUCAGON (GCG) in stage 7 derived from Ctr-iPSCs and FOXA2+/− iPSCs. C Flow cytometry quantification for the data shown in B. D qPCR quantification for the expression of the pancreatic markers, FOXA2, INS, GCG, ABCC8, KCNJ11, NKX6.1, NKX2.2, and PDX1 in beta cells derived from Ctr-iPSCs and FOXA2+/− iPSCs. GSIS assay: fold change of C-PEPTIDE secretion in iPSC-derived beta cells challenged with low (LG; 2.8 mM) and high glucose (HG; 20 mM) (E) or stimulated with or without 30 mM KCl in the presence of LG (F). Data are represented as mean ± SD; *p < 0.05, **p < 0.01, ***p < 0.001.
